文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

经导管心肌切开术缓解左室流出道梗阻的初步经验

Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction.
PubMed 文献 · J Am Coll Cardiol · 2024-03-11

该单中心回顾性研究纳入2021至2023年76例接受SESAME手术的患者,其中11例为经典HCM,余为辅助TMVR或TAVR。所有患者均实现心肌撕裂,TMVR后neo-LVOT及skirt-neo-LVOT显著改善,HCM患者静息LVOT压差显著下降。手术存活率97.4%,不良事件包括室间隔缺损和心室游离壁穿孔(各3.9%),永久起搏器植入率5.3%。

要点

  • SESAME可有效增加TMVR后neo-LVOT面积并降低HCM患者静息LVOT压差。
  • 手术存活率高,但需注意室间隔缺损和心室穿孔风险。
  • 永久起搏器植入率较低,但部分与同期TAVR相关。

核心结论

  • SESAME手术在HCM及瓣膜置换后LVOT梗阻患者中技术可行,可改善血流动力学,但需进一步积累经验。

研究设计与样本

  • 单中心回顾性研究,2021至2023年纳入76例接受SESAME手术的患者。

主要发现

  • 所有患者均实现技术成功的SESAME心肌撕裂。
  • TMVR后neo-LVOT从42 mm²(Q1-Q3: 7-117)增至170 mm²(Q1-Q3: 95-265),P<0.001;skirt-neo-LVOT从169 mm²(Q1-Q3: 153-193)增至214 mm²(Q1-Q3: 180-262),P<0.001。
  • HCM患者静息LVOT压差从54 mm Hg(Q1-Q3: 40-70)降至29 mm Hg(Q1-Q3: 12-36),P=0.023;激发后压差从146 mm Hg(Q1-Q3: 100-180)降至85 mm Hg(Q1-Q3: 40-120),P=0.076。
  • 74例(97.4%)存活手术;3例(3.9%)发生医源性室间隔缺损无需修复,3例(3.9%)心室游离壁穿孔,均未发生于HCM患者。
  • 4例(5.3%)需永久起搏器,其中2例在同期TAVR后。

临床怎么用

  • 对于HCM伴LVOT梗阻或需辅助TMVR/TAVR的患者,SESAME可考虑作为改善LVOT梗阻的治疗选择。

局限性

  • 单中心回顾性研究,样本量有限,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a source of morbidity in hypertrophic cardiomyopathy (HCM) and a life-threatening complication of transcatheter mitral valve replacement (TMVR) and transcatheter aortic valve replacement (TAVR). Available surgical and transcatheter approaches are limited by high surgical risk, unsuitable septal perforators, and heart block requiring permanent pacemakers. OBJECTIVES: The authors report the initial experience of a novel transcatheter electrosurgical procedure developed to mimic surgical myotomy. METHODS: We used septal scoring along midline endocardium (SESAME) to treat patients, on a compassionate basis, with symptomatic LVOT obstruction or to create space to facilitate TMVR or TAVR. RESULTS: In this single-center retrospective study between 2021 and 2023, 76 patients underwent SESAME. In total, 11 (14%) had classic HCM, and the remainder underwent SESAME to facilitate TMVR or TAVR. All had technically successful SESAME myocardial laceration. Measures to predict post-TMVR LVOT significantly improved (neo-LVOT 42 mm2 [Q1-Q3: 7-117 mm2] to 170 mm2 [Q1-Q3: 95-265 mm2]; P < 0.001; skirt-neo-LVOT 169 mm2 [Q1-Q3: 153-193 mm2] to 214 mm2 [Q1-Q3: 180-262 mm2]; P < 0.001). Among patients with HCM, SESAME significantly decreased invasive LVOT gradients (resting: 54 mm Hg [Q1-Q3: 40-70 mm Hg] to 29 mm Hg [Q1-Q3: 12-36 mm Hg]; P = 0.023; provoked 146 mm Hg [Q1-Q3: 100-180 mm Hg] to 85 mm Hg [Q1-Q3: 40-120 mm Hg]; P = 0.076). A total of 74 (97.4%) survived the procedure. Five experienced 3 of 76 (3.9%) iatrogenic ventricular septal defects that did not require repair and 3 of 76 (3.9%) ventricular free wall perforations. Neither occurred in patients treated for HCM. Permanent pacemakers were required in 4 of 76 (5.3%), including 2 after concomitant TAVR. Lacerations were stable and did not propagate after SESAME (remaining septum: 5.9 ± 3.3 mm to 6.1 ± 3.2 mm; P = 0.8). CONCLUSIONS: With further experience, SESAME may benefit patients requiring septal reduction therapy for obstructive hypertrophic cardiomyopathy as well as those with LVOT obstruction after heart valve replacement, and/or can help facilitate transcatheter valve implantation.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Greenbaum AB, Ueyama HA, Gleason PT, et al. Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction. J Am Coll Cardiol. 2024. PMID: 38471643. doi:10.1016/j.jacc.2024.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。